News
Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.
4d
Zacks Investment Research on MSNCan Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...
The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable ...
Novo Nordisk Foundation & Denmark invest €80M in a Microsoft-powered quantum computer to boost Nordic tech innovation.
The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...
Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...
6d
TipRanks on MSNNovo Nordisk’s IcoSema Study: A New Horizon in Diabetes TreatmentNovo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has completed a 40-week clinical study titled ‘A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results